MiniMed Group (MMED) Stock Looks Below Fair Value While Growth Questions Linger

MiniMed Group has already delivered a strong year for shareholders, yet the stock still screens as cheap on broad valuation checks. With the share price moving higher and the market multiple view flagging the stock as undervalued, the key issue is whether that apparent discount is justified by fundamentals or expectations have run ahead of themselves.

• Year to date, MiniMed Group is up 28.9%, which puts fresh attention on whether the recent share price level leaves enough room for further upside.
• Progress on products such as MiniMed Fit and MiniMed Flex can support optimism about future revenue, while execution risk around new sensor launches and broader growth expectations may weigh on how much investors are willing to pay today.
• With a high value score of 5, the broader checks lean cheap and suggest MiniMed Group is not priced as aggressively as many growth focused healthcare stocks.

For investors, the debate is whether MiniMed Group’s strong share price run has already captured most of that apparent value gap or whether the current level still leaves a margin that looks attractive on the usual multiples.

Compare MiniMed Group’s strong year to date move with a hand picked list of other companies that also screen as attractively priced on valuation checks through the 53 high quality undervalued stocks.

Does MiniMed Group Look Undervalued on Sales?

P/S is often a useful way to look at MiniMed Group because revenue tends to be more stable than earnings for medical equipment companies investing heavily in growth. MiniMed Group currently trades on a P/S of 2.1x, which is below the Medical Equipment industry average of about 3.0x and the peer group average of roughly 3.1x.

The fair P/S ratio, which blends the company’s growth profile, margins, size and risk, is estimated at 2.8x. That level is above the current 2.1x, which indicates a valuation that is less demanding than sector norms. Despite the recent upgrade to fiscal 2027 organic revenue guidance and the stronger start to the year, the stock still trades at a discount to typical medical equipment peers on this sales-based measure.

On the P/S multiple, MiniMed Group stock appears undervalued compared with both its fair ratio and the wider medical equipment sector.

See what the numbers say about this price — find out in our valuation breakdown.

The MiniMed Group Narrative: What Would Justify Today's Price?

For MiniMed Group, Simply Wall St Narratives pick up where the valuation puzzle leaves off and explain what combination of future growth, margins and earnings would need to occur for the stock to be worth materially more or less than today’s price. Each narrative links its number to a clear view of how MiniMed Group's growth, profitability and risk profile might evolve, which you can revisit on the Community page as fresh information becomes available.

Share a narrative on MiniMed Group stock to present your number-driven view on whether the recent growth acceleration and product pipeline progress, including MiniMed Fit and MiniMed Flex, support the current price. Add your voice to the Simply Wall St community and track how your thesis holds up as new results come through.

Do you think there's more to the story for MiniMed Group? Head over to our Community to see what others are saying!

The Bottom Line

MiniMed Group still screens as undervalued on market multiples, even after a strong year to date share price move. The key question now is whether the current discount reflects conservative expectations or a fair premium for execution risk around new products and growth targets. The crux for investors is whether MiniMed Group can deliver on revenue and margin ambitions quickly enough for the market to close that gap, rather than leaving the stock as a value trap within the medical equipment sector.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com